Jan. 28, 2025 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced positive initial data ...
Leap Therapeutics, Inc.'s DKN-01 showed disappointing results in the DisTinGuish trial for gastric and gastroesophageal junction cancer. The DeFianCe trial in colorectal cancer was closer to ...
On Wednesday, H.C. Wainwright adjusted its stance on Leap Therapeutics (NASDAQ:LPTX), downgrading the biopharmaceutical company's stock rating from Buy to Neutral. The downgrade has intensified ...
On Wednesday, Baird analyst Joel Beatty revised the rating on Leap Therapeutics (NASDAQ:LPTX) stock, moving from Outperform to Neutral. This adjustment comes alongside a significant reduction in ...
Leap Therapeutics (NASDAQ:LPTX) fell ~12% on Wednesday as Baird downgraded the stock after the biotech said its lead candidate, sirexatamab, generated disappointing data in a mid-stage trial for ...
Jan. 28, 2025 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced positive initial data ...
Leap Therapeutics stock opened at $0.52 on Wednesday. Leap Therapeutics has a one year low of $0.51 and a one year high of $4.79. The company has a 50-day simple moving average of $2.78 and a 200 ...
Get Our Latest Research Report on Leap Therapeutics Leap Therapeutics Trading Up 7.9 % NASDAQ LPTX opened at $0.56 on Thursday. The company has a market capitalization of $21.46 million, a PE ...
Shares of Leap Therapeutics slid after disappointing initial data from two mid-stage clinical trials of its oncology treatment, resulting in the discontinuation of one clinical program.